Jubilant Biosys has achieved an early-stage milestone in their collaborative partnership with Sanofi focused on metabolic disorders. The milestone reflects the successful transition of a program to the next phase in the discovery and development process.   The alliance started in 2016 and focuses on the discovery and development of small molecule inhibitors for multiple targets designed to address the unmet medical needs in diabetes and obesity. Jubilant Biosys will continue to apply its...